Previous close | 109.00 |
Open | 108.09 |
Bid | 107.52 x 900 |
Ask | 108.71 x 800 |
Day's range | 107.55 - 108.80 |
52-week range | 101.24 - 142.60 |
Volume | |
Avg. volume | 5,097,395 |
Market cap | 188.974B |
Beta (5Y monthly) | 0.70 |
PE ratio (TTM) | 22.53 |
EPS (TTM) | 4.79 |
Earnings date | 18 Oct 2022 - 24 Oct 2022 |
Forward dividend & yield | 1.88 (1.72%) |
Ex-dividend date | 14 Jul 2022 |
1y target est | 127.91 |
This week, in legal news Yahoo Finance is following stalled legislation that would have reined in Big Tech; lawsuits piling up against formula maker Abbott; and a simmering legal feud between Twitter and Tesla CEO Elon Musk.
Abbott Laboratories' growth looks much less impressive after removing sales from COVID-19 diagnostics.
Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.